A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
Recruiting
Phase 2
Interventional Study
Atopic Dermatitis (AD)
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 225 (estimated)
- Sponsor
- Bluefin Biomedicine, Inc. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Are adults (18-75) with a diagnosis of atopic dermatitis for at least one year.
* Have moderate to severe disease not adequately controlled by topical treatments.
* Are willing to follow study instructions, attend regular visits, and avoid certain other medications during the …
Contacts